|
|
|
European Biopharmaceutical Review
|
Initially, many smaller biologic drug substances − including recombinant proteins and peptides − were produced via microbial fermentation. However, with the advent of cell culture systems, interest shifted to mammalian systems to produce larger proteins and antibodies. Now, the introduction of smaller, complex next-generation molecules, such as bioconjugates, antibody fragments, and other scaffolds, are once again driving interest in fermentation as an effective manufacturing platform.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Ardena expands capacity to satisfy Novavax COVID vaccine demand
Gent, Belgium/December 2021: Ardena, a specialist pharmaceutical
contract development and manufacturing organisation (CDMO), announced it
will be expanding its capacity for purification and fractionation of
GMP manufacturing at its site in Södertälje, Sweden. The expansion will
satisfy long-term demand expected from Novavax for production of the
company’s COVID-19 vaccine, among others.
More info >> |
|
 |
White Papers |
 |
|
Comparator Sourcing in Oncology Trials
Clinical Services International
This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >> |
|
|
.jpg)
